Orchid's PDE-4 inhibitor shows early promise in European study
This article was originally published in Scrip
Executive Summary
Orchid Chemicals & Pharmaceuticals expects to start Phase IIa studies in Europe by March with its oral phosphodiesterase-4 (PDE-4) inhibitor OCID 2987 for inflammatory disorders including chronic obstructive pulmonary disease (COPD), following promising early clinical results from a trial in the Netherlands.